These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 35335032)

  • 1. Efficacy and Safety of Heterologous Booster Vaccination after Ad5-nCoV (CanSino Biologics) Vaccine: A Preliminary Descriptive Study.
    Muñoz-Valle JF; Sánchez-Zuno GA; Matuz-Flores MG; Hernández-Ramírez CO; Díaz-Pérez SA; Baños-Hernández CJ; Turrubiates-Hernández FJ; Vega-Magaña AN; Hernández-Bello J
    Vaccines (Basel); 2022 Mar; 10(3):. PubMed ID: 35335032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
    Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
    Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralizing Antibodies against SARS-CoV-2, Anti-Ad5 Antibodies, and Reactogenicity in Response to Ad5-nCoV (CanSino Biologics) Vaccine in Individuals with and without Prior SARS-CoV-2.
    Hernández-Bello J; Morales-Núñez JJ; Machado-Sulbarán AC; Díaz-Pérez SA; Torres-Hernández PC; Balcázar-Félix P; Gutiérrez-Brito JA; Lomelí-Nieto JA; Muñoz-Valle JF
    Vaccines (Basel); 2021 Sep; 9(9):. PubMed ID: 34579284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IgG Antibodies Generation and Side Effects Caused by Ad5-nCoV Vaccine (CanSino Biologics) and BNT162b2 Vaccine (Pfizer/BioNTech) among Mexican Population.
    Guzmán-Martínez O; Guardado K; de Guevara EL; Navarro S; Hernández C; Zenteno-Cuevas R; Montero H
    Vaccines (Basel); 2021 Sep; 9(9):. PubMed ID: 34579236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of three different COVID-19 vaccine platforms (CoronaVac, BTN162b2, and Ad5-nCoV) in individuals with and without prior COVID-19: Reactogenicity and neutralizing antibodies.
    Morales-Núñez JJ; Muñoz-Valle JF; Machado-Sulbarán AC; Díaz-Pérez SA; Torres-Hernández PC; Panduro-Espinoza BV; Gallegos-Díaz de Leon JA; Munguía-Ramirez CD; Hernández-Bello J
    Immunol Lett; 2022 Dec; 251-252():20-28. PubMed ID: 36279685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
    Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA
    EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of efficacy and antibody duration to fourth-dose booster of Ad5-nCoV or inactivated SARS-CoV-2 vaccine in Chinese adults: a prospective cohort study.
    Xu N; Xu Y; Dai R; Zheng L; Qin P; Wan P; Yang Y; Jiang J; Zhang H; Hu X; Lv H
    Front Immunol; 2023; 14():1244373. PubMed ID: 37736100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Heterologous Vaccination Regimen with Ad5-nCoV CanSinoBio and BNT162b2 Pfizer in SARS-CoV-2 IgG Antibodies Titers.
    Romero-Ibarguengoitia ME; Rivera-Salinas D; Hernández-Ruíz YG; Armendariz-Vázquez AG; González-Cantú A; Barco-Flores IA; González-Facio R; Montelongo-Cruz LP; Del Rio-Parra GF; Sanz-Sánchez MÁ
    Vaccines (Basel); 2022 Mar; 10(3):. PubMed ID: 35335024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and efficacy of          heterologous ChAdOx1-BNT162b2 vaccination.
    Pozzetto B; Legros V; Djebali S; Barateau V; Guibert N; Villard M; Peyrot L; Allatif O; Fassier JB; Massardier-Pilonchéry A; Brengel-Pesce K; Yaugel-Novoa M; Denolly S; Boson B; Bourlet T; Bal A; Valette M; Andrieu T; Lina B; ; Cosset FL; Paul S; Defrance T; Marvel J; Walzer T; Trouillet-Assant S
    Nature; 2021 Dec; 600(7890):701-706. PubMed ID: 34673755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralizing antibody responses to the Delta variant of SARS-CoV-2 following vaccination with Ad5-nCoV (CanSino) in the Mexican population.
    Hernández-Bello J; Lorenzo-Leal AC; Muñoz-Valle JF; Morales-Núñez JJ; Díaz-Pérez SA; Hernández-Gutiérrez R; Bach H
    PLoS One; 2024; 19(4):e0299520. PubMed ID: 38573914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.
    Havervall S; Marking U; Greilert-Norin N; Ng H; Gordon M; Salomonsson AC; Hellström C; Pin E; Blom K; Mangsbo S; Phillipson M; Klingström J; Hober S; Nilsson P; Åberg M; Thålin C
    EBioMedicine; 2021 Aug; 70():103523. PubMed ID: 34391088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines.
    Marking U; Havervall S; Greilert-Norin N; Ng H; Blom K; Nilsson P; Phillipson M; Hober S; Nilsson C; Mangsbo S; Christ W; Klingström J; Gordon M; Åberg M; Thålin C
    Vaccines (Basel); 2022 Feb; 10(3):. PubMed ID: 35334989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines.
    Rogliani P; Chetta A; Cazzola M; Calzetta L
    Vaccines (Basel); 2021 Mar; 9(3):. PubMed ID: 33807818
    [No Abstract]   [Full Text] [Related]  

  • 15. Neutralizing antibodies levels are increased in individuals with heterologous vaccination and hybrid immunity with Ad5-nCoV in the north of Mexico.
    Cervantes-Luevano K; Espino-Vazquez AN; Flores-Acosta G; Bernaldez-Sarabia J; Cabanillas-Bernal O; Gasperin-Bulbarela J; Gonzalez-Sanchez R; Comas-Garcia A; Licea-Navarro AF
    PLoS One; 2022; 17(6):e0269032. PubMed ID: 35749390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study.
    Esquivel-Valerio JA; Skinner-Taylor CM; Moreno-Arquieta IA; Cardenas-de la Garza JA; Garcia-Arellano G; Gonzalez-Garcia PL; Almaraz-Juarez FDR; Galarza-Delgado DA
    Rheumatol Int; 2021 Dec; 41(12):2105-2108. PubMed ID: 34622311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased neutralization of SARS-CoV-2 Delta variant after heterologous ChAdOx1 nCoV-19/BNT162b2 versus homologous BNT162b2 vaccination.
    Bauswein M; Peterhoff D; Plentz A; Hiergeist A; Wagner R; Gessner A; Salzberger B; Schmidt B; Bauernfeind S
    iScience; 2022 Feb; 25(2):103694. PubMed ID: 35013723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humoral Response Induced by Prime-Boost Vaccination with the ChAdOx1 nCoV-19 and mRNA BNT162b2 Vaccines in a Teriflunomide-Treated Multiple Sclerosis Patient.
    Michiels Y; Houhou-Fidouh N; Collin G; Berger J; Kohli E
    Vaccines (Basel); 2021 Oct; 9(10):. PubMed ID: 34696248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2.
    Reiter R; Von Blanckenburg P; Mutters R; Thiemer J; Geßner R; Seifart U
    Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A China-developed adenovirus vector-based COVID-19 vaccine: review of the development and application of Ad5-nCov.
    Wang SY; Liu WQ; Li YQ; Li JX; Zhu FC
    Expert Rev Vaccines; 2023; 22(1):704-713. PubMed ID: 37501516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.